VIPR Corporation (OTC:VIPV) is a CBD company focused on acquiring, developing and designing branded products for the Hemp-based CBD health and wellness sector. VIPR markets its CBD products to retailers in the health and wellness space throughout North America, and also available for sale on our wholly owned Kronique CBD online store.
The Hemp-based CBD market is expected to exceed US$20 billion per annum in the United States alone, by 2024. The fact that CBD market was only recently legitimized in the US by the passage of 2018 US Farm Bill, illustrates the explosive growth opportunity that VIPR has strategically targeted.
The massive opportunity within the CBD market is the lack of any established dominant brands, and this is exactly the void that VIPR and Kronique are targeting.
VIPR Corporation (OTC:VIPV) is a CBD company focused on acquiring, developing and designing branded products for the Hemp-based CBD health and wellness sector. VIPR markets its CBD products to retailers in the health and wellness space throughout North America, and also available for sale on our wholly owned Kronique CBD online store.
The Hemp-based CBD market is expected to exceed US$20 billion per annum in the United States alone, by 2024. The fact that CBD market was only recently legitimized in the US by the passage of 2018 US Farm Bill, illustrates the explosive growth opportunity that VIPR has strategically targeted.
The massive opportunity within the CBD market is the lack of any established dominant brands, and this is exactly the void that VIPR and Kronique are targeting.
Kronique is a signature brand of hemp-based CBD products targeting the emo Kronique was established as a nutraceutical lifestyle brand, that embraces the concept of nature-based remedies designed for the global health and wellness market.
One of the primary applications for CBD based products is the lucrative pain management market. Estimated to eclipse US$77 billion per annum by 2023, the global pain management offers one of the most exciting opportunities for the Kronique brand.
Consumers are increasingly turning towards nature based remedies, or nutraceuticals, to address their pain management needs.
The timing is perfect for massive growth opportunities with CBD products well positioned as a viable alternative to traditional prescription medications.
Opioid addiction is increasingly being recognized as a massive global epidemic, and there is a critical need in the pain relief market for non-addictive pain relief alternative that is viable for longer term use. There is significant medical research that reinforces the fact that CBD’s significantly help patients with their pain management needs. And CBD’s are both non-addictive and affordable.
Kronique’s signature product line has been developed to provide relief to consumers for both pain management, and anxiety and depression disorders. The anxiety disorder market is expected exceed US$18.5 billion per annum by 2025, and like pain management, prescription medications for this disorder are considered highly addictive. Consumers have increasingly turned to CBD products as a non-addictive treatment solution that is both safe and affordable.
Kronique has sourced it’s hemp based CBD supply from one of the United State’s leading state of the art facilities. Products are all
VIPR Corporation (OTC:VIPV)
The investor center
Paw CBD, a pet division of cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a nationally recognized consumer cannabidiol (CBD) brand, has launched its newly
Paw CBD, a pet division of cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a nationally recognized consumer cannabidiol (CBD) brand, has launched its newly
Paw CBD, a pet division of cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a nationally recognized consumer cannabidiol (CBD) brand, has launched its newly